Cite
HARVARD Citation
Kolev, V. et al. (n.d.). 281 VS-5584, a dual PI3K/mTOR inhibitor, demonstrates robust activity in pre-clinical models of SCLC with the inhibition of both cancer stem cells and bulk tumor cells. European journal of cancer. pp. S53-. [Online].